Clinical Trials
71 trialsA Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
TEADCO
Orion Corporation, Orion Pharma
eVOLVE-Meso
AstraZeneca
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
ANTARES
Instituto do Cancer do Estado de São Paulo
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Metro-PD1
Centre Oscar Lambret
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune, Inc.
CD8 PET Imaging in Metastatic Solid Tumours
University Medical Center Groningen
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
CheckMate 6DW
Bristol-Myers Squibb
DREAM3R
PrECOG, LLC.
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Sanofi
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center
CheckMate142
Bristol-Myers Squibb
IMPALA
University Hospital, Lille
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NIPISAFE
GERCOR - Multidisciplinary Oncology Cooperative Group
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Exelixis
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Ono Pharmaceutical Co., Ltd.
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Bristol-Myers Squibb
CONFIRM
University of Southampton
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
myDAvIpNi
Universitair Ziekenhuis Brussel
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
CheckMate743
Bristol-Myers Squibb
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Enlivex Therapeutics RDO Ltd.
NIPU
Oslo University Hospital
NIMBLe
Canadian Cancer Trials Group
RACIN
Centre Hospitalier Universitaire Vaudois
RELATIVITY-111
Bristol-Myers Squibb
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago